Pituitary Tumors: Molecular Insights, Diagnosis, and Targeted Therapy—Third Edition
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: 31 October 2026 | Viewed by 904
Special Issue Editors
Interests: Cushing’s disease; hypopituitarism; pituitary tumor; proopiomelanocortin; stress
Special Issues, Collections and Topics in MDPI journals
Interests: corticotropin-releasing hormone; Cushing’s disease; glucocorticoid; hypopituitarism; proopiomelanocortin
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
We are happy to launch the third installment in the Special Issue series "Pituitary Tumors: Molecular Insights, Diagnosis, and Targeted Therapy”, following the success of the first (https://www.mdpi.com/journal/cancers/special_issues/PTMDT) and second (https://www.mdpi.com/journal/cancers/special_issues/D866VYVP2P) editions.
Pituitary tumors present a variety of hormonal activities and clinical features, some overt and others subtle. Functioning pituitary tumors are defined based on the autonomous/dysregulated secretion of pituitary hormones. In this Special Issue, we will explore recent molecular insights and advances in diagnosis and targeted therapy in pituitary tumors. For example, Cushing’s disease is defined by the autonomous secretion of ACTH and excess cortisol production, which are clearly manifested in the disease’s clinical features. Mutations in the ubiquitin-specific protease (USP) 8 or USP48 genes have been detected in Cushing’s disease. Hormones produced from pituitary tumors sometimes induce severe complications such as hypertension, hyperglycemia, osteoporosis, infections, atherosclerosis, and mental health disorders. The pathophysiological characteristics of hormone production and pituitary adenoma cells remain to be elucidated. In addition, the usefulness and accuracy of recent diagnostic criteria for pituitary tumors also need to be evaluated. The primary treatment for some types of pituitary tumors is the surgical excision of the adenoma from the pituitary; however, curative surgery is still challenging, and additional therapies are required to treat the resulting hypersecretion of hormones and tumor growth. This Special Issue will include original basic/translational/clinical research articles and reviews on aspects related to the pathophysiology, diagnosis, and potential treatment of pituitary tumors.
In recognition of your contributions to this field, we invite you and your group to submit a review or original research article to this Special Issue. The submission period will close on 31 October 2026. For submission information, please consult the Cancers website below and submit your manuscript via the online submission form, making reference to the Special Issue “Pituitary Tumors: Molecular Insights, Diagnosis, and Targeted Therapy—Third Edition”.
We look forward to receiving your contributions.
Sincerely,
Dr. Kazunori Kageyama
Dr. Mitsuru Nishiyama
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- acromegaly
- adrenocorticotropic hormone
- Cushing’s disease
- diagnosis
- growth hormone
- pituitary tumor
- proliferation
- transcriptional factor
- treatment
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
